A Finnish trial has shown no significant improvement in the outcomes of patients with early rheumatoid arthritis who are monitored using an automated text message-enhanced approach versus the standard approach.
Patients with ankylosing spondylitis have a significantly increased risk for venous thromboembolism compared with the general population, with the risk apparently highest in the first year after diagnosis, study findings indicate.
Patients who are treated with ibuprofen alone experience comparable pain control in the first day after hip replacement to those give acetaminophen plus ibuprofen, findings from the PANSAID trial suggest.
Findings from a multi-database study suggest that rheumatoid arthritis patients treated with tocilizumab do not have a higher overall risk for serious infection than those treated with tumor necrosis factor inhibitors, but their risk for certain types of infection may be elevated.
Over a 1-year period, around one in four individuals with hip and/or knee osteoarthritis received opioids for pain management, compared with approximately one in 10 people without such a diagnosis, finds a Swedish population-based study.
Two post-hoc analyses published in RMD Open indicate that treatment with the Janus kinase inhibitor tofacitinib is associated with an improvement in patient-reported outcomes among individuals with psoriatic arthritis.
A magnetic resonance imaging-guided treat-to-target strategy does not improve disease activity or slow joint damage progression compared with a conventional strategy in patients with rheumatoid arthritis in clinical remission, research shows.
The addition of belimumab to maintenance therapy with azathioprine and low-dose glucocorticoids does not improve maintenance of remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, findings from the BREVAS trial suggest.
Findings from two registry-based studies suggest that tocilizumab and rituximab may be associated with better treatment outcomes than abatacept and tumour necrosis factor inhibitors among patients with rheumatoid arthritis.
Elevated levels of fecal calprotectin, an indicator of gut inflammation, are associated with increased disease activity and reduced physical function in patients with axial spondyloarthritis, research shows.
Inflammatory bowel disease is an “uncommon” occurrence among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis who are treated with the interleukin-17A inhibitor secukinumab, researchers report.
Women with rheumatoid arthritis have a significantly lower chance of having a live birth following assisted reproductive technology treatment than women without RA, researchers report in the Annals of the Rheumatic Diseases.
A genome-wide association study has identified novel genetic variants associated with osteoarthritis susceptibility, opening the path for the development of new drugs and repositioning of existing therapeutics.
A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.